CagriSemaNovo NordiskInsurance Coverage Outlook

Formulary Tier

Expected: Tier 3 or Tier 4
Based on Wegovy patterns (same manufacturer). Tier 4 (specialty) more likely for obesity indication. Copays: $100–$200 (Tier 3), $150–$500 (Tier 4). High efficacy (22.7%) may support Tier 3 placement.

Prior Authorization

Expected: Required
Your doctor will submit clinical documentation proving medical necessity: BMI ≥30 (or ≥27 with comorbidity), weight-related comorbidities, prior lifestyle interventions documented, no contraindications (history of pancreatitis, MEN2, medullary thyroid cancer).

Step Therapy

Possible
Some plans may require trying Wegovy or other GLP-1s first before approving CagriSema. However, dual-mechanism (GLP-1 + amylin) may support step therapy exceptions if single-mechanism GLP-1s failed.

Novo Nordisk Advantage

Established Payer Relationships:
• Novo Nordisk has existing coverage agreements for Wegovy/Ozempic
• May smooth CagriSema's formulary negotiations vs. new manufacturers
• Strong manufacturer savings programs expected ($25-$100/month copay cards)
• Patient assistance programs for uninsured/underinsured patients

Obesity Indication (2026-2027 Projected Coverage)

Not a Bridge Drug
By law, basic Medicare Part D coverage excludes drugs used for weight loss. The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers only Wegovy (injection and pill), Foundayo, and the Zepbound KwikPen for weight loss, for $50 per monthly fill with conditions; CagriSema is not a Bridge drug, and CMS has not announced what replaces the Bridge after December 31, 2027.

Type 2 Diabetes Indication (If Approved)

Broad Coverage Expected
If CagriSema is approved for type 2 diabetes (REDEFINE 2 trial showed 15.7% weight loss in T2D patients), it may be covered under Medicare Part D for diabetes management, subject to plan formularies and prior authorization—similar to Ozempic today.

Out-of-Pocket Costs (2026-2027 Projections)

Lower Than Current Landscape
Medicare negotiated pricing with manufacturers started in 2026. Depending on negotiation outcomes, copays may range from $50-$200/month (vs. current $200-$500 for non-negotiated GLP-1s).

Important Evolution

2025 vs. 2026-2027:
Current Medicare policies prohibit obesity-only coverage for most beneficiaries. By CagriSema's launch, obesity treatment may be mainstream Medicare coverage if legislative trends (Treat and Reduce Obesity Act) pass or CMS adds it to a program like the Medicare GLP-1 Bridge. High efficacy (22.7%) strengthens coverage arguments.

States with GLP-1 Coverage (2025 Baseline)

13 states (as of January 2026)
These state Medicaid programs covered GLP-1s for obesity (per KFF). States change often: Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026, while NC Medicaid reinstated obesity GLP-1 coverage on December 12, 2025. By 2026-2027, this number will likely expand as states see cost savings from reduced diabetes and cardiovascular disease.

High Efficacy Cost Argument

May Improve State Coverage
CagriSema's 22.7% weight loss provides stronger cost-effectiveness arguments than lower-efficacy GLP-1s. States may view high-efficacy drugs as better long-term investments due to superior comorbidity reduction.

Prior Authorization Requirements

Typically Required
States that cover GLP-1s usually require:
• BMI ≥30 (or ≥27 with comorbidity)
• 6-12 months documented weight-loss attempts
• Participation in behavioral weight-loss program
• Regular follow-up visits and adherence monitoring

2026-2027 Outlook

More States, Broader Coverage:
By CagriSema's launch, Medicaid GLP-1 coverage will likely be more widespread due to:
1. Accumulating evidence of cost savings (reduced diabetes, cardiovascular events)
2. Federal incentives or mandates (if obesity coverage becomes ACA-required preventive service)
3. Competitive pressure (neighboring states with coverage may drive expansion)
4. High-efficacy drugs like CagriSema demonstrating superior outcomes

What It Is: Prior authorization requires your doctor to submit clinical documentation to your insurance company before they'll approve coverage. The insurer reviews your medical history, BMI, comorbidities, and prior treatments to determine if CagriSema is "medically necessary."

Why It Exists: Insurers use PA to control costs and ensure medications are used appropriately. For expensive medications like CagriSema, PA helps prevent off-label use and ensures patients meet clinical criteria.

How to Overcome:

• Work with your doctor to submit a complete PA form with all required documentation
• Include a detailed letter of medical necessity explaining why CagriSema is appropriate (e.g., dual-mechanism provides superior efficacy vs. single GLP-1s)
• Document your BMI, weight-related comorbidities (cardiovascular disease, diabetes, sleep apnea), and prior weight-loss attempts
• Emphasize 22.7% efficacy advantage if prior lower-efficacy GLP-1s provided inadequate response
• If denied, appeal immediately with additional supporting evidence

What It Is: Step therapy requires you to try and fail less expensive treatments (like Wegovy or Zepbound) before your insurer will approve CagriSema. This can delay access by 3-6 months.

Why It Exists: Step therapy controls costs by ensuring patients start with lower-cost interventions. If those work, expensive newer medications aren't needed.

How to Overcome:

• Document prior treatment failures thoroughly (medications tried, duration, outcomes)
• Request a step therapy exception if you have contraindications to single-mechanism GLP-1s
• Demonstrate why dual-mechanism (GLP-1 + amylin) is medically superior for you (e.g., prior GLP-1 monotherapy provided inadequate weight loss)
• Emphasize CagriSema's unique mechanism: true synergy between cagrilintide and semaglutide exceeds either component alone

What It Is: Quantity limits restrict how much medication you can receive per fill. For CagriSema (weekly injections), this typically means 30-day supplies (4-5 pens) rather than 90-day supplies.

Why It Exists: Insurers use quantity limits to monitor high-cost medication use and reduce waste.

How to Overcome:

• Request 90-day supplies if your plan permits (reduces pharmacy visits and copays)
• Demonstrate adherence with 30-day fills first, then request quantity limit increases
• Use specialty pharmacy (often required for Tier 4 drugs) which may have higher quantity limits

What It Is: Some plans completely exclude obesity medications from coverage, meaning no amount of appeals will result in approval.

Why It Exists: Employers and insurers may exclude entire drug classes (like obesity medications) to control costs.

How to Overcome:

• Check your plan's formulary BEFORE CagriSema launches to confirm obesity medications aren't excluded
• If excluded, appeal to your employer's HR department during open enrollment (2026-2027)
• Consider switching plans during open enrollment to one that covers obesity medications
• Explore manufacturer savings programs (Novo Nordisk will likely offer copay assistance)
• If you have type 2 diabetes, emphasize diabetes indication rather than weight loss alone